Trial Profile
Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Fluoxetine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 10 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as no participant enrolled.
- 04 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020 as reported by ClinicalTrials.gov.
- 04 Feb 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020 as reported by ClinicalTrials.gov.